In a significant stride toward transforming the landscape of joint disease treatment, Enveric Biosciences has inked two non-binding term sheets with a yet undisclosed biotechnology company. This promising collaboration is poised to steer the future of both pharmaceutical and non-pharmaceutical applications using innovative cannabinoid-COX-2 conjugate compounds. Situated in Cambridge, Massachusetts, Enveric’s latest move aligns with its robust agenda of pushing the boundaries in medical biotechnology.
